Jupiter Neurosciences (NASDAQ:JUNS) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Jupiter Neurosciences (NASDAQ:JUNS) released its quarterly earnings data on Thursday. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01), FiscalAI reports. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.23 million.

Jupiter Neurosciences Stock Down 3.3%

Shares of JUNS stock traded down $0.01 during mid-day trading on Friday, reaching $0.34. 40,053 shares of the stock traded hands, compared to its average volume of 88,968. The stock’s fifty day simple moving average is $0.38 and its two-hundred day simple moving average is $0.78. Jupiter Neurosciences has a 1-year low of $0.31 and a 1-year high of $3.33. The company has a market cap of $12.26 million, a price-to-earnings ratio of -1.25 and a beta of 2.16.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Institutional Trading of Jupiter Neurosciences

A hedge fund recently raised its stake in Jupiter Neurosciences stock. Geode Capital Management LLC grew its position in shares of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) by 27.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 132,641 shares of the company’s stock after purchasing an additional 28,826 shares during the quarter. Geode Capital Management LLC owned approximately 0.39% of Jupiter Neurosciences worth $135,000 as of its most recent SEC filing.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.